Humira clears conditional approval requirement in Japan
This article was originally published in Scrip
Executive Summary
Abbott and co-promotion partner Eisai have completed an all-patient postmarketing surveillance programme in Japan for Humira (adalimumab), which has confirmed the safety and efficacy of the product in local patients with rheumatoid arthritis.